Like restrictive diets and intense exercise, GLP-1 treatments can lead to muscle mass loss unless used in combination with nutritional advice, such as specific daily protein targets
This positive outcome is primarily attributed to the weight loss associated with GLP-1 therapy, underscoring its dual role in effectively managing both diabetes and obesity
Furthermore, it slows gastric emptying, which leads to a more gradual absorption of glucose
Herein, we describe the discovery of the orally bioavailable, small-molecule, GLP-1R agonist PF-06882961 (danuglipron)
Sukhumvit, Silom, Sathorn, Asok, Phrom Phong, Thonglor, Ratchada, Lat Phrao
Conversely, if an individual encounters adverse reactions, a decrease in dosage might be advised to enhance tolerability